company background image
SGHT

Sight SciencesNasdaqGS:SGHT Stock Report

Last Price

US$14.88

Market Cap

US$703.9m

7D

-13.6%

1Y

n/a

Updated

19 Jan, 2022

Data

Company Financials +
SGHT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

SGHT Stock Overview

Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Sight Sciences
Historical stock prices
Current Share PriceUS$14.88
52 Week HighUS$42.57
52 Week LowUS$14.10
Beta0
1 Month Change-17.33%
3 Month Change-42.68%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-55.58%

Recent News & Updates

Jan 13

Sight Sciences: Appeal Is Visually Increasing

Sight Sciences has seen its shares been cut in half compared to the first price after the IPO this past summer. This pullback came while top line sales developments have been solid and another FDA clearance has rolled in. Given this nice setup, I see appeal clearly increasing here.

Shareholder Returns

SGHTUS Medical EquipmentUS Market
7D-13.6%-4.8%-4.6%
1Yn/a-0.4%7.7%

Return vs Industry: Insufficient data to determine how SGHT performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how SGHT performed against the US Market.

Price Volatility

Is SGHT's price volatile compared to industry and market?
SGHT volatility
SGHT Average Weekly Movement10.4%
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.6%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.4%

Stable Share Price: SGHT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: SGHT's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2010169Paul Badawihttps://www.sightsciences.com

Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company’s products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States.

Sight Sciences Fundamentals Summary

How do Sight Sciences's earnings and revenue compare to its market cap?
SGHT fundamental statistics
Market CapUS$703.94m
Earnings (TTM)-US$56.13m
Revenue (TTM)US$43.26m

16.3x

P/S Ratio

-12.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SGHT income statement (TTM)
RevenueUS$43.26m
Cost of RevenueUS$9.04m
Gross ProfitUS$34.22m
ExpensesUS$90.35m
Earnings-US$56.13m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.19
Gross Margin79.09%
Net Profit Margin-129.74%
Debt/Equity Ratio13.2%

How did SGHT perform over the long term?

See historical performance and comparison

Valuation

Is Sight Sciences undervalued compared to its fair value and its price relative to the market?

2.86x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SGHT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SGHT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SGHT is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: SGHT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SGHT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SGHT is good value based on its PB Ratio (2.9x) compared to the US Medical Equipment industry average (3.5x).


Future Growth

How is Sight Sciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-3.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SGHT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SGHT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SGHT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SGHT's revenue (48.3% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: SGHT's revenue (48.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SGHT is forecast to be unprofitable in 3 years.


Past Performance

How has Sight Sciences performed over the past 5 years?

-72.8%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: SGHT is currently unprofitable.

Growing Profit Margin: SGHT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if SGHT's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare SGHT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SGHT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).


Return on Equity

High ROE: SGHT has a negative Return on Equity (-22.82%), as it is currently unprofitable.


Financial Health

How is Sight Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: SGHT's short term assets ($287.8M) exceed its short term liabilities ($10.3M).

Long Term Liabilities: SGHT's short term assets ($287.8M) exceed its long term liabilities ($34.8M).


Debt to Equity History and Analysis

Debt Level: SGHT has more cash than its total debt.

Reducing Debt: Insufficient data to determine if SGHT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SGHT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: SGHT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 34.4% each year


Dividend

What is Sight Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SGHT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SGHT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SGHT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SGHT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SGHT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average management tenure


CEO

Paul Badawi (46 yo)

11yrs

Tenure

US$496,710

Compensation

Mr. Paul Badawi is a Co-Founder of Sight Sciences, Inc. since 2011 and serves as its President and Chief Executive Officer since 2011. Mr. Badawi specializes in medical technology investments for 3i. His p...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD496.71K) is below average for companies of similar size in the US market ($USD2.39M).

Compensation vs Earnings: Insufficient data to compare Paul's compensation with company performance.


Leadership Team

Experienced Management: SGHT's management team is considered experienced (4.1 years average tenure).


Board Members

Experienced Board: SGHT's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SGHT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: SGHT only recently listed within the past 12 months.


Top Shareholders

Company Information

Sight Sciences, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Sight Sciences, Inc.
  • Ticker: SGHT
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$703.935m
  • Shares outstanding: 47.31m
  • Website: https://www.sightsciences.com

Number of Employees


Location

  • Sight Sciences, Inc.
  • 4040 Campbell Avenue
  • Suite 100
  • Menlo Park
  • California
  • 94025
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 23:47
End of Day Share Price2022/01/19 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.